• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转铁蛋白修饰的卡洛芬铂(IV)纳米颗粒作为具有肿瘤靶向、抑制炎症、抑制上皮-间充质转化和激活免疫特性的抗转移剂。

Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial-Mesenchymal Transition Suppression, and Immune Activation Properties.

机构信息

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, P. R. China.

Key Laboratory of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, P. R. China.

出版信息

J Med Chem. 2024 Sep 26;67(18):16416-16434. doi: 10.1021/acs.jmedchem.4c01265. Epub 2024 Sep 5.

DOI:10.1021/acs.jmedchem.4c01265
PMID:39235464
Abstract

The inflammatory microenvironment is a central driver of tumor metastasis, intimately associated with the promotion of epithelial-mesenchymal transition (EMT) and immune suppression. Here, transferrin-modified carprofen platinum(IV) nanoparticles Tf-NPs@CPF-Pt(IV) with promising antiproliferative and antimetastatic properties were developed, which activated by inhibiting inflammation, suppressing EMT, and activating immune responses besides causing DNA injury. The nanoparticles released the active ingredient CPF-Pt(IV) in a sustained manner and offered enhanced pharmacokinetic properties compared to free CPF-Pt(IV) in vivo. Additionally, they possessed satisfactory tumor targeting effects via the transferrin motif. Serious DNA damage was induced with the upregulation of γ-H2AX and P53, and the mitochondria-mediated apoptotic pathway Bcl-2/Bax/caspase3 was initiated. Inflammation was alleviated by inhibiting COX-2 and MMP9 and decreasing inflammatory cytokines TNF-α and IL-6. Subsequently, the EMT was reversed by inhibiting the Wnt/β-catenin pathway. Furthermore, the antitumor immunity was provoked by blocking the immune checkpoint PD-L1 and increasing CD3 and CD8 T lymphocytes in tumors.

摘要

炎症微环境是肿瘤转移的核心驱动因素,与促进上皮-间充质转化 (EMT) 和免疫抑制密切相关。在这里,开发了具有有前景的抗增殖和抗转移特性的转铁蛋白修饰的卡洛芬铂(IV)纳米颗粒 Tf-NPs@CPF-Pt(IV),除了引起 DNA 损伤外,它还通过抑制炎症、抑制 EMT 和激活免疫反应来激活。与体内游离 CPF-Pt(IV) 相比,纳米颗粒以持续的方式释放有效成分 CPF-Pt(IV),并具有增强的药代动力学特性。此外,它们通过转铁蛋白基序具有令人满意的肿瘤靶向效果。通过上调 γ-H2AX 和 P53 诱导严重的 DNA 损伤,并启动线粒体介导的凋亡途径 Bcl-2/Bax/caspase3。通过抑制 COX-2 和 MMP9 以及降低炎症细胞因子 TNF-α 和 IL-6 来减轻炎症。随后,通过阻断免疫检查点 PD-L1 并增加肿瘤中的 CD3 和 CD8 T 淋巴细胞来逆转 EMT。

相似文献

1
Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial-Mesenchymal Transition Suppression, and Immune Activation Properties.转铁蛋白修饰的卡洛芬铂(IV)纳米颗粒作为具有肿瘤靶向、抑制炎症、抑制上皮-间充质转化和激活免疫特性的抗转移剂。
J Med Chem. 2024 Sep 26;67(18):16416-16434. doi: 10.1021/acs.jmedchem.4c01265. Epub 2024 Sep 5.
2
Canadine Platinum(IV) Complexes Targeting Epithelial-Mesenchymal Transition as Antiproliferative and Antimetastatic Agents.靶向上皮-间充质转化的 Canadine 铂(IV)配合物作为抗增殖和抗转移剂。
J Med Chem. 2024 Aug 8;67(15):12868-12886. doi: 10.1021/acs.jmedchem.4c00843. Epub 2024 Jul 28.
3
Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling.熊去氧胆酸铂(IV)缀合物作为抗增殖和抗转移剂:通过抑制 JAK2/STAT3 信号通路重塑肿瘤微环境。
J Med Chem. 2024 Oct 10;67(19):17551-17567. doi: 10.1021/acs.jmedchem.4c01549. Epub 2024 Sep 18.
4
A hydroxychloroquine platinum(IV) conjugate displaying potent antimetastatic activities by suppressing autophagy to improve the tumor microenvironment.一种羟氯喹铂(IV)缀合物,通过抑制自噬来改善肿瘤微环境,从而显示出强大的抗转移活性。
Dalton Trans. 2024 Aug 20;53(33):13890-13905. doi: 10.1039/d4dt01794c.
5
Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial-Mesenchymal Transition and Arousing Immune Response.一系列地氯雷他定铂(IV)杂化物通过抑制上皮-间充质转化和引发免疫反应显示出强大的抗转移能力。
J Med Chem. 2024 Feb 8;67(3):2031-2048. doi: 10.1021/acs.jmedchem.3c01845. Epub 2024 Jan 17.
6
Multi-specific niflumic acid platinum(IV) complexes displaying potent antitumor activities by improving immunity and suppressing angiogenesis besides causing DNA damage.多特异性尼氟灭酸铂(IV)复合物通过改善免疫和抑制血管生成以及引起 DNA 损伤来发挥强大的抗肿瘤活性。
Dalton Trans. 2022 Dec 20;52(1):147-158. doi: 10.1039/d2dt03246e.
7
Development of Clioquinol Platinum(IV) Conjugates as Autophagy-Targeted Antimetastatic Agents.开发胶氯酚铂(IV)缀合物作为自噬靶向抗转移药物。
J Med Chem. 2023 Mar 9;66(5):3393-3410. doi: 10.1021/acs.jmedchem.2c01895. Epub 2023 Feb 22.
8
Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response.酮洛芬和洛索洛芬铂(IV)配合物通过诱导 DNA 损伤、抑制炎症和增强免疫反应显示出抗肿瘤转移活性。
J Med Chem. 2021 Dec 23;64(24):17920-17935. doi: 10.1021/acs.jmedchem.1c01236. Epub 2021 Dec 1.
9
Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(iv) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism.二氢喹啉铂(IV)杂化物的设计、合成及抗肿瘤活性研究——以线粒体损伤和 DNA 损伤为作用机制
Dalton Trans. 2021 Jan 7;50(1):362-375. doi: 10.1039/d0dt03194a. Epub 2020 Dec 15.
10
Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.萘普生铂(IV)杂化物抑制环氧化酶和基质金属蛋白酶并导致 DNA 损伤:作为体外和体内抗肿瘤剂的合成和生物学评价。
Dalton Trans. 2020 Apr 28;49(16):5192-5204. doi: 10.1039/d0dt00424c.

引用本文的文献

1
Unveiling the nexus of p53 and PD-L1: insights into immunotherapy resistance mechanisms in hepatocellular carcinoma.揭示p53与PD-L1的联系:深入了解肝细胞癌免疫治疗耐药机制
Am J Cancer Res. 2025 Apr 15;15(4):1410-1435. doi: 10.62347/BRTO3272. eCollection 2025.
2
Synthesis Methods and Therapeutic Journey of Carprofen and Its Derivatives: A Review.卡洛芬及其衍生物的合成方法与治疗历程:综述
Chem Biol Drug Des. 2025 May;105(5):e70122. doi: 10.1111/cbdd.70122.